Evidence map›Paper›PMID 37812235›Full record

ArticleRheumatology (Oxford, England)2024

Serum alarmins and the risk of incident interstitial lung disease in rheumatoid arthritis.

Jill A Poole, Bryant R England, Harlan Sayles, Tate M Johnson, Michael J Duryee, Carlos D Hunter, Joshua F Baker, Gail S Kerr, Gary Kunkel, Grant W Cannon and 6 more

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Rheumatology (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Monocyte-mediated mechanisms in idiopathic pulmonary fibrosis: opportunities for early intervention.Apoptosis : an international journal on programmed cell death · 2026
    Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Jill A PooleDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Bryant R EnglandDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.ORCID 0000-0002-9649-3588
Harlan SaylesDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.ORCID 0000-0002-4082-8289
Tate M JohnsonDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Michael J DuryeeDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Carlos D HunterDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Joshua F BakerCorporal Michael J. Crescenz Veterans Affairs Medical Center, School of Medicine and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-0799-7563
Gail S KerrWashington, D.C. VA, Georgetown and Howard University, Washington, DC, USA.
Gary KunkelGeorge E. Wahlen Veterans Affairs Medical Center, University of Utah, Salt Lake City, UT, USA.
Grant W CannonGeorge E. Wahlen Veterans Affairs Medical Center, University of Utah, Salt Lake City, UT, USA.
Brian C SauerGeorge E. Wahlen Veterans Affairs Medical Center, University of Utah, Salt Lake City, UT, USA.
Katherine D WyshamVA Puget Sound Health Care System, University of Washington, Seattle, WA, USA.
Amy M JosephVA St. Louis Health Care System, Washington University School of Medicine, St Louis, MO, USA.
Beth I WallaceVA Ann Arbor Healthcare System, University of Michigan Medical School, Ann Arbor, MI, USA.
Geoffrey M ThieleDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Ted R MikulsDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Nebraska Medical Center · USUniversity of Utah · USHoward University · USPhiladelphia VA Medical Center · USUniversity of Michigan · USUniversity of Washington · USVA St. Louis Health Care System · US

Funding

Tracking and Evaluation CoreU54GM115458 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI RIZZO, MATTHEW · 2016 to 2025
$42.8M
Resolving Occupational Exposure-Induced Lung DiseaseR01OH012045 · OH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI POOLE, JILL A · 2021 to 2024
$2.3M
A Pragmatic Trial to Determine the Benefit of Behaviorally Enhanced Exercise Incentives and Corticosteroid Injections in Osteoarthritis of the KneeI01RX003644 · VA · PHILADELPHIA VA MEDICAL CENTER · PI BAKER, JOSHUA F. · 2022 to 2025
–
Improving the Management of Rheumatoid Arthritis-Associated Lung Disease in Veterans Using Real-World DataIK2CX002203 · VA · OMAHA VA MEDICAL CENTER · PI Bryant R England · 2021 to 2026
–
Pathogenic Role of Malondialdehyde-Acetaldehyde Adducts in Rheumatoid ArthritisI01BX004660 · VA · OMAHA VA MEDICAL CENTER · PI MIKULS, TED RICHARD · 2020 to 2023
–
Using SMART Design to Develop Dynamic Treatment Regimens for Glucocorticoid TaperingIK2CX002430 · VA · VETERANS HEALTH ADMINISTRATION · PI Beth Ilene Wallace · 2022 to 2026
–
Quantifying the Impact of Frailty on Osteoporosis and Fractures in Veterans with Rheumatoid ArthritisIK2CX002351 · VA · VA PUGET SOUND HEALTHCARE SYSTEM · PI Katherine D Wysham · 2022 to 2026
–
Adipokines as Biomarkers of Cachexia and High-Risk Rheumatoid ArthritisI01CX001703 · VA · PHILADELPHIA VA MEDICAL CENTER · PI BAKER, JOSHUA F. · 2019 to 2023
–
BLRD VA I01 BX003635BLRD VA I01 BX004660Central States Center of Agricultural Safety and HealthCSRD VA I01 CX001703CSRD VA IK2 CX002203CSRD VA IK2 CX002351CSRD VA IK2 CX002430Department of Defense PR200793NIGMS NIH HHS U54 GM115458NIH HHS 2U54GM115458NIOSH CDC HHS R01 OH012045NIOSH CDC HHS R01OH012045Rheumatology Research FoundationRR&D Merit RX0003644RRD VA I01 RX003644VA CSR&D CX002351VA CSR&D CX002430-01VA CSR&D Merit CX0001703
6 · The paper itself

Abstract

objectivesTo quantify associations of serum alarmins with risk of rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

methodsUsing serum collected at enrolment, three alarmins (IL-33, thymic stromal lymphopoietin [TSLP] and IL-25) were measured in a multicentre prospective RA cohort. ILD was classified using systematic medical record review. Cross-sectional associations of log-transformed (IL-33, TSLP) or quartile (IL-25) values with RA-ILD at enrolment (prevalent RA-ILD) were examined using logistic regression, while associations with incident RA-ILD developing after enrolment were examined using Cox proportional hazards. Covariates in multivariate models included age, sex, race, smoking status, RA disease activity score and anti-cyclic citrullinated antibody positivity.

resultsOf 2835 study participants, 115 participants (4.1%) had prevalent RA-ILD at baseline and an additional 146 (5.1%) developed incident ILD. There were no associations between serum alarmin concentrations and prevalent ILD in unadjusted or adjusted logistic regression models. In contrast, there was a significant inverse association between IL-33 concentration and the risk of developing incident RA-ILD in unadjusted (hazard ratio [HR] 0.73 per log-fold increase; 95% CI: 0.57, 0.95; P = 0.018) and adjusted (HR 0.77; 95% CI: 0.59, 1.00; P = 0.047) models. No significant associations of TSLP or IL-25 with incident ILD were observed.

conclusionIn this study, we observed a significant inverse association between serum IL-33 concentration and the risk of developing incident RA-ILD, but no associations with prevalent ILD. Additional investigation is required to better understand the mechanisms driving this relationship and how serum alarmin IL-33 assessment might contribute to clinical risk stratification in patients with RA.

Indexed as

AlarminsArthritis, RheumatoidCytokinesInterleukin-33Lung Diseases, InterstitialAgedBiomarkersCross-Sectional StudiesFemaleHumansIncidenceInterleukin-17MaleMiddle AgedProspective StudiesRisk FactorsAlarminsBiomarkersCytokinesIL25 protein, humanIL33 protein, humanInterleukin-17Interleukin-33Thymic Stromal Lymphopoietinalarminfibrosisinterleukin-25interleukin-33interstitial lung diseaserheumatoid arthritisthymic stromal lymphopoietin

Identifiers

PMID37812235
PMCPMC11215989
OpenAlexW4387439579

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.